SOUTH SAN FRANCISCO, Calif.,
Aug. 30, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ: IDYA), a synthetic lethality-focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics, announced its participation in investor
conferences in September 2021.
Citi's 16th Annual BioPharma Virtual Conference
Yujiro Hata, Chief Executive
Officer, will participate in a panel discussion entitled "Aiming
for the Bull's Eye – Latest Advances in Targeted Oncology" on
Friday, September 10, 2021 at
9:45am ET. The panel discussion
will be hosted by Yigal Nochomovitz,
Ph.D. Director, Equity Research. The panelists include:
- Yujiro Hata, Chief Executive Officer, IDEAYA
Biosciences
- Terry Rosen, Chief Executive
Officer, Arcus Biosciences
- Jacob Chacko, Chief
Executive Officer, ORIC
Pharmaceuticals
- Avanish Vellanki, Chief
Executive Officer, Rain Therapeutics
- Briggs Morrison, Chief
Executive Officer, Syndax Pharmaceuticals
H.C. Wainwright 23rd Annual Global Investment
Conference
Paul Stone, Chief Financial Officer,
will present on Monday, September 13,
2021 at 7:00am ET
R. W. Baird 2021 Virtual Global Healthcare Conference
Fireside chat with Yujiro Hata,
Chief Executive Officer hosted by Joel
Beatty, M.D. C.F.A., Senior Research Analyst
Wednesday, September 15, 2021 at
4:20pm ET
2021 Cantor Virtual Global Healthcare Conference
Paul Stone, Chief Financial Officer,
will present on Thursday, September 30,
2021 at 11:20am ET
A live audio webcast of each event will be available, as
permitted by conference host, at the "Investors/News and
Events/Investor Calendar" section of the IDEAYA website at
https://ir.ideayabio.com/events. A replay of available
webcasts will be accessible for 30 days following the live
event.
About IDEAYA Biosciences
IDEAYA is a synthetic
lethality-focused precision medicine oncology company committed to
the discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's
approach integrates capabilities in identifying and validating
translational biomarkers with drug discovery to select patient
populations most likely to benefit from its targeted
therapies. IDEAYA is applying its early research and drug
discovery capabilities to synthetic lethality – which represents an
emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to participation in and/or presentation at
certain investor relations events. IDEAYA undertakes no obligation
to update or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the business of IDEAYA in
general, see IDEAYA's Quarterly Report on Form 10-Q filed
on August 10, 2021 and any current and periodic reports filed
with the U.S. Securities and Exchange Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-investor-conferences-in-september-2021-301364421.html
SOURCE IDEAYA Biosciences, Inc.